The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Radionetics Oncology Forms Strategic Relationship with Eli Lilly and Company
Jul 01, 2024•almost 2 years ago
Contract Type
agreement
San DiegoPharmaceutical Manufacturing
Description
Radionetics Oncology has formed a strategic relationship with Eli Lilly and Company, under which Radionetics received a $140 million upfront cash payment, and Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion. This relationship provides access to novel GPCR targets and the discovery capabilities of Radionetics Oncology.
Company Information
Company
Radionetics Oncology
Location
70 WILLOW STREET
San Diego, California, United States
About
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.
San DiegoPharmaceutical Manufacturing